News | January 28, 2025
RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
EBITDA margins expand to 31.3%
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Subscribe To Our Newsletter & Stay Updated
